Skip to main content

Table 4 Prognostic factors to predict treatment response after topotecan and cyclophosphamide containing induction therapy (univariate analysis)

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

  Response ≥ 90% Response < 90% Crude OR
(95% CI)
p-value
Age 3.5 ± 2.5 4.1 ± 2.6 1.09
(0.93–1.28)
0.307
Gender
Male 28 (45.2) 34 (54.8) 1  
Female 14 (31.1) 31 (68.9) 1.82
(0.82–4.08)
0.140
Grade of differentiation
Poorly differentiate & Undifferentiate 26 (40.0) 39 (60.0) 1  
Differentiate 3 (37.5) 5 (62.5) 1.11
(0.24–5.06)
0.892
MYNC
Non-amplified 17 (43.6) 22 (56.4) 1  
Amplified 3 (25.0) 9 (75.0) 2.32
(0.54–9.9)
0.256
Shimada histology
Favorable 4 (44.4) 5 (55.6) 1  
Unfavorable 10 (43.5) 13 (56.5) 1.04
(0.22–4.91)
0.960
NSE 314.1 ± 398.9 415.7 ± 420.6 1.00
(1.00–1.00)
0.222
VMA 45.3 ± 93.3 22.7 ± 33.1 0.99
(0.99–1.00)
0.115
Health care system
University-based 37 (45.7) 44 (54.3) 1  
Community-based 5 (19.2) 21 (80.8) 3.53
(1.21–10.28)
0.021
  1. Notes: Data are categorical variables and presented as number (%) except for age, NSE and VMA which are continuous variables and presented as mean ± SD. Univariate analysis was calculated using logistic regression. p-value < 0.05 is considered as statistical significance
  2. Abbreviations: NSE serum neuron-specific enolase (ng/mL); VMA urine vanillylmandelic acid (mg/day)
\